Strategic partnership strengthens pharma links between China and MENA

EVA Pharma and Zhejiang Jinhua Conba Bio-Pharm have announced a strategic agreement aimed at improving the security and accessibility of pharmaceutical supply chains between China and the Middle East & Africa.

The two pharmaceutical leaders formalised the deal during CPHI China 2025, agreeing to collaborate on building a more robust and responsive supply infrastructure for essential medicines. The partnership brings together EVA Pharma’s regional distribution capabilities with Conba Bio-Pharm’s manufacturing expertise, creating a platform to deliver high-quality treatments to underserved populations.

EVA Pharma, headquartered in Cairo, has played a key role in expanding access to healthcare across the Middle East and Africa. Its CEO, Riad Armanious, described the partnership as “a pivotal move toward more resilient, agile, and affordable cross-border supply networks.” He added: “At a time when supply reliability is more critical than ever, this agreement reinforces our mission to get vital medicines to the people who need them most.”

“Our collaboration with EVA Pharma highlights a shared goal - to make healthcare more accessible by combining world-class manufacturing with strong regional delivery channels,” said Mr  Bin Yu, President of Zhejiang Jinhua CONBA Bio-Pharm.

More information online